STOCK TITAN
  1. Home
  2. News
  3. ENDV

NDONOVO THERAPEUTICS INC - $ENDV STOCK NEWS

Welcome to our dedicated page for NDONOVO THERAPEUTICS news (Ticker: $ENDV), a resource for investors and traders seeking the latest updates and insights on NDONOVO THERAPEUTICS stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NDONOVO THERAPEUTICS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NDONOVO THERAPEUTICS's position in the market.

News
Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc
Rhea-AI Summary
Endonovo (ENDV) and SofPulse, Inc. have finalized the Asset Purchase Agreement for the acquisition of Endonovo's assets and IP for a minimum of $50 million. SofPulse, Inc. will issue $50 million in stock to ENDV shareholders and raise up to $1 million in capital. SofPulse, Inc. aims to drive revenue growth through expanded distribution and international market penetration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.78%
Tags
none
-
News
Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions
Rhea-AI Summary
SofPulse Inc., a subsidiary of Endonovo (ENDV), announced its participation in the US Army Medical Research and Development Command Vendor Day to showcase its FDA-cleared medical device, SofPulse®, for pain management solutions in the VA and DoD systems. The device has shown significant pain reduction benefits and decreased opioid requirements post-surgery. SofPulse® plans to expand its presence in VA/DoD facilities through partnerships and attendance at medical conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million
Rhea-AI Summary
Endonovo Therapeutics, Inc. (OTCQB: ENDV) has signed a definitive agreement to sell its SofPulse® business and medical IP to SofPulse, Inc. for a minimum of $50 million. SofPulse, Inc. aims to conduct a capital raise of up to $500,000 through a 506 offering tailored for accredited investors. The company plans to explore growth opportunities and expand its revenue to approximately $100 million by 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30%
Tags
none
News
Endonovo's SofPulse® Secures Taiwan FDA Approval
Rhea-AI Summary
Endonovo Therapeutics receives regulatory approval for SofPulse® in Taiwan
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8%
Tags
fda approval
-
News
Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution
Rhea-AI Summary
Endonovo Therapeutics included on Federal Supply Schedule for SofPulse® PEMF medical devices, paving the way for distribution in government healthcare sectors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.56%
Tags
none
-
News
Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
none
News
Endonovo Pending Agreement to Develop Telehealth Division
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Endonovo Launches SofPulse® into the Veterans Administration
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
none
-
News
Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.63%
Tags
clinical trial
News
Endonovo Announces Partnership with Former NFL Dallas Cowboy Defensive Lineman
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.23%
Tags
partnership
Stock ENDV logo
NDONOVO THERAPEUTICS INC

OTC:ENDV

ENDV Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ENDV Stock Data

860.63k
243.40M
24.7%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Woodland Hills

About ENDV

endonovo therapeutics (otcqb: endv) is an innovative biotechnology company developing a bioelectronic approach to regenerative medicine. endonovo's immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and necrosis, and the promotion of regeneration. endonovo's cytotronics™ platform provides for a method of expanding and manipulating cells using simulated microgravity and time-varying electromagnetic fields (tvemf) for tissue engineering and cell therapies.